Oshkosh Corporation Named to Computerworld 2026 List of Best Places to Work in IT for Fifth Consecutive Year
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Key Terms
pulmonary arterial hypertensionmedical
Pulmonary arterial hypertension is a progressive medical condition in which the arteries that carry blood from the heart to the lungs become narrowed or stiff, causing high pressure in the lung circulation and extra strain on the heart — like a pump working against clogged pipes. For investors, it matters because the condition defines the need, market size, clinical trial design, regulatory hurdles and potential revenue or risk for companies developing drugs, devices or diagnostics to treat or manage it.
phase 2bmedical
Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.
non-cystic fibrosis bronchiectasismedical
A chronic lung condition in which the airways become permanently widened and scarred, making them less able to clear mucus and more prone to repeated infections; think of damaged plumbing that traps debris and breeds clogs. It matters to investors because a persistent patient population with ongoing infections and hospital visits creates steady demand for drugs, diagnostics, inhaled therapies, and medical services, which can affect revenues and R&D priorities in healthcare and biotech.
pseudomonas aeruginosamedical
Pseudomonas aeruginosa is a common bacterium that can cause serious infections, especially in hospitals or people with weakened immune systems. Investors care because it is often resistant to many antibiotics, driving demand for new drugs, diagnostics, and infection-control products while also creating potential regulatory hurdles, clinical trial challenges, and liability risks for healthcare-related companies—think of it as a stubborn, hard-to-remove stain that increases costs and uncertainty for businesses involved in treatment and prevention.
A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.
inhalation powdermedical
A dose of medication manufactured as a dry powder that is inhaled into the lungs using a handheld device rather than swallowed or injected. Think of it like a measured spoonful of powdered spice delivered through a shaker built to fit the airway; the powder must reach specific lung regions to work. Investors care because the drug's safety, ease of use, manufacturing costs, device patents and regulatory pathway all affect commercial success and market value.
OSHKOSH, Wis.--(BUSINESS WIRE)--
Oshkosh Corporation (NYSE: OSK), a leading innovator of purpose-built vehicles, equipment and services, has been recognized as one of Computerworld’s Best Places to Work in IT for 2026. This marks the fifth consecutive year of recognition for the company.
Oshkosh Corporation, a leading innovator of purpose-built vehicles, equipment and services, has been recognized as one of Computerworld’s Best Places to Work in IT for 2026. This marks the fifth consecutive year of recognition for the company.
“Being named one of the Best Places to Work in IT reflects the strength of our culture and the passion of our Digital Technology team,” said Anupam Khare, senior vice president and chief information officer, Oshkosh Corporation. “At Oshkosh, our values guide how we live our purpose — creating an environment that cultivates innovation, fosters collaboration and empowers every team member to grow and make a meaningful impact.”
The Best Places to Work in IT list is an annual ranking of the top work environments for technology professionals by Foundry's Computerworld. The list is compiled based on a comprehensive questionnaire regarding company offerings in categories such as benefits, career development and training, workplace culture, workplace modernization, IT growth and employee engagement and retention. In addition, the rankings are reviewed and vetted by a panel of industry experts.
To learn more about Oshkosh Corporation and how our team members are fulfilling our purpose of “making a difference in people’s lives,” visit oshkoshcorp.com. A complete list of award recipients can be viewed on Computerworld’s website.
About Oshkosh Corporation
At Oshkosh (NYSE: OSK), we make innovative, purpose-built equipment to help everyday heroes advance communities around the world. Headquartered in Wisconsin, Oshkosh Corporation employs over 18,000 team members worldwide, all united behind a common purpose: to make a difference in people’s lives. Oshkosh products can be found in more than 150 countries under the brands of JLG®, Pierce®, MAXIMETAL, Oshkosh® S-Series™, McNeilus®, IMT®, Jerr-Dan®, Frontline™ Communications, Oshkosh® Airport Products, Oshkosh AeroTech™, Oshkosh® Defense and Pratt Miller. For more information, visit oshkoshcorp.com.
®, ™ All brand names referred to in this news release are trademarks of Oshkosh Corporation or its subsidiary companies.
